

endoret® (prgf®)

Endogenous Regenerative Technology

OSTEOARTHRITIS

ONLY ENDORET HAS DEMONSTRATED EFFICACY IN TWO CLINICAL TRIALS OF LEVEL I AMONG ALL PLASMA RICH IN GROWTH FACTORS

ENTROA⁽¹⁾

ENDORET® TREATMENT FOR OSTEOARTHRITIS



ARTHROSCOPY
THE JOURNAL OF ARTHROSCOPIC
AND RELATED SURGERY

Randomized clinical trial for the evaluation of Endoret (prgf) compared to Hyaluronic acid in the treatment of symptomatic osteoarthritis of the knee.

ENDORET® DECREASES SIGNIFICANTLY THE PAIN AND THE RIGIDITY OF THE OSTEOARTHRITIS OF THE KNEE (2) (3) (4) (5)

70% OF PATIENTS IMPROVED WITH ENDORET® (1)


During the study period, Endoret **reduced pain more and more effectively** while the efficacy of hyaluronic acid was gradually reduced.

None of the patients treated with Endoret presented **adverse reactions to the treatment.**

% OF PATIENTS WITH A **SIGNIFICANT** REDUCTION IN PAIN[&] 6 MONTHS AFTER TREATMENT

* p<0.05%

[&] Defined as a reduction of 50% on the WOMAC Index



(1) Sánchez M, Fiz N, Azofra J, Usabiaga J, Aduriz Recalde E, García Gutiérrez A, Albillos J, Gárate R, Aguirre JJ, Padilla S, Orive G, and Anitua E. A Randomized Clinical Trial Evaluating Plasma Rich in Growth Factors (PRGF-Endoret) Versus Hyaluronic Acid in the Short-Term Treatment of Symptomatic Knee Osteoarthritis. *Arthroscopy*, 2012. Vol 28, No 8 (August): pp 1070-1078.
(2) Andía I, Sánchez M, Maffulli N. Joint pathology and platelet-rich plasma therapies. *Expert Opin Biol Ther*. 2012;12:7-22.
(3) Anitua E, Sánchez M, de la Fuente M, Azofra J, Zaldueño M, Aguirre JJ, Andía I. Relationship between Investigative Biomarkers and Radiographic Grading in Patients with Knee Osteoarthritis. *Int J Rheumatol*. 2009;2009:747432.
(4) Anitua E, Sánchez M, Nurden AT, Zaldueño MM, de la Fuente M, Azofra J, Andía I. Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. *Rheumatology (Oxford)*. 2007;46:1769-1772.
(5) Anitua E, Sanchez M, De la Fuente M, Zaldueño MM, Orive G. Plasma rich in growth factors (PRGF-Endoret) stimulates tendon and synovial fibroblasts migration and improves the biological properties of hyaluronic acid. *Knee Surg Sports Traumatol Arthrosc*. 2012.

ABSTRACT

Mikel Sánchez, Ph.D., Nicolás Fiz, Ph.D., Juan Azofra, Ph.D., Jaime Usabiaga, Ph.D., Enmanuel Aduriz Recalde, Ph.D., Antonio Garcia Gutierrez, Ph.D., Javier Albillos, Ph.D., Ramón Gárate, Ph.D., Jose Javier Aguirre, Sabino Padilla, Ph.D., Gorka Orive, Ph.D., and Eduardo Anitua, M.D., D.D.S., Ph.D.

A Randomized Clinical Trial Evaluating Plasma Rich in Growth Factors (PRGF-Endoret) Versus Hyaluronic Acid in the Short-Term Treatment of Symptomatic Knee Osteoarthritis.

PURPOSE

This multicenter, double-blind clinical trial evaluated and compared the efficacy and safety of PRGF-Endoret (BTI Biotechnology Institute, Vitoria-Gasteiz, Spain), an autologous biological therapy for regenerative purposes, versus hyaluronic acid (HA) as a short-term treatment for knee pain from osteoarthritis.

METHODS

We randomly assigned 176 patients with symptomatic knee osteoarthritis to receive infiltrations with PRGF-Endoret or with HA (3 injections on a weekly basis). The primary outcome measure was a 50% decrease in knee pain from baseline to week 24. As secondary outcomes, we also assessed pain, stiffness, and physical function using the Western Ontario and McMaster Universities Osteoarthritis Index; the rate of response using the criteria of the Outcome Measures for Rheumatology Committee and Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative (OMERACT-OARSI); and safety.

RESULTS

The mean age of the patients was 59.8 years, and 52% were women. Compared with the rate of response to HA, the rate of response to PRGF-Endoret was 14.1 percentage points higher (95% confidence interval, 0.5 to 27.6; $P = .044$). Regarding the secondary outcome measures, the rate of response to PRGF-Endoret was higher in all cases, although no significant differences were reached. Adverse events were mild and evenly distributed between the groups.

CONCLUSIONS

Plasma rich in growth factors showed superior short-term results when compared with HA in a randomized controlled trial, with a comparable safety profile, in alleviating symptoms of mild to moderate osteoarthritis of the knee. Level of

EVIDENCE

Level I, randomized controlled multicenter trial.